Soluble guanylate cyclase: A potential therapeutic target for heart failure

Heart Failure Reviews

Volumn 18, Issue 2, 2013, Pages 123-134

  Gheorghiade, Mihai ^a   Marti, Catherine N ^b   Sabbah, Hani N ^c   Roessig, Lothar ^d   Greene, Stephen J ^a   Böhm, Michael ^e   Burnett, John C ^f   Campia, Umberto ^a   Cleland, John G F ^g   Collins, Sean P ^h   Fonarow, Gregg C ⁱ   Levy, Phillip D ^j   Metra, Marco ^k   Pitt, Bertram ^l   Ponikowski, Piotr ^m   Sato, Naoki ⁿ   Voors, Adriaan A ^o   Stasch, Johannes Peter ^d   Butler, Javed ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d BAYER PHARMA AG   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f MAYO CLINIC   (United States)

^g CASTLE HILL HOSPITAL   (United Kingdom)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

^k UNIVERSITY OF BRESCIA   (Italy)

^l UNIVERSITY OF MICHIGAN   (United States)

^m WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁿ NIPPON MEDICAL SCHOOL   (Japan)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

Cyclic guanosine monophosphate; Heart failure; Pathophysiology; Soluble guanylate cyclase; Treatment

Indexed keywords

CINACIGUAT; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; NELOCIGUAT; NITRIC OXIDE; PLACEBO; RIOCIGUAT;

ACUTE HEART FAILURE; ADD ON THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROGNOSIS; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

CYCLIC GMP; GUANYLATE CYCLASE; HEART FAILURE; HEMODYNAMICS; HUMANS; NITRIC OXIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84878222682     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-012-9323-1     Document Type: Article

References (93)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121(7):e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667
2. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296(18):2217-2226. doi: 10.1001/jama.296.18.2217 (Pubitemid 44708052)
3. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319-1331. doi: 10.1001/jama.297.12.1319 (Pubitemid 46513233)
4. Wilcox JE, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Heywood JT, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Gheorghiade M (2012) Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J 163(1):49-56.e2. doi: 10.1016/j.ahj.2011.10.001
5. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Pina IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N (2009) Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 157(6):957-970. doi: 10.1016/j.ahj.2009.04.010
6. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112(25):3958-3968. doi: 10.1161/CIRCULATIONAHA.105.590091 (Pubitemid 43739494)
7. Gheorghiade M, Peterson ED (2011) Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. JAMA 305(23):2456-2457. doi: 10.1001/jama.2011.836
8. Bock JS, Gottlieb SS (2010) Cardiorenal syndrome: new perspectives. Circulation 121(23):2592-2600. doi: 10.1161/CIRCULATIONAHA.109.886473
9. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P (1997) Apoptosis in the failing human heart. New England J Med 336(16):1131-1141. doi: 10.1056/NEJM199704173361603 (Pubitemid 27374695)
10. Whelan RS, Kaplinskiy V, Kitsis RN (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72:19-44. doi: 10.1146/annurev.physiol.010908.163111
11. Paulus WJ, Bronzwaer JG (2004) Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol 287(1):H8-13 (Pubitemid 38802330)
12. Mohan P, Brutsaert DL, Paulus WJ, Sys SU (1996) Myocardial contractile response to nitric oxide and cGMP. Circulation 93(6):1223-1229 (Pubitemid 26087026)
13. Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, Dewerchin M, Bloch KD, Janssens S, Brouckaert P (2008) Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice. Cardiovasc Res 79(1):179-186 (Pubitemid 351881935)
14. Paulus WJ, Vantrimpont PJ, Shah AM (1994) Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 89(5):2070-2078 (Pubitemid 24142783)
15. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, Lerebours G, Thuillez C (2000) Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 102(3):351-356 (Pubitemid 30457588)
16. Kojda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E (1996) Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 78(1):91-101 (Pubitemid 26004125)
17. Ito N, Bartunek J, Spitzer KW, Lorell BH (1997) Effects of the nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes. Circulation 95(9):2303-2311 (Pubitemid 27191009)
18. + in intact cardiac myocytes. Circ Res 74(5):970-978
19. Munzel T, Gori T, Bruno RM, Taddei S (2010) Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 31:2741-2748
20. Ontkean M, Gay R, Greenberg B (1991) Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69(4):1088-1096
21. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M (2009) Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 196(2):193-222
22. Schmidt HH, Hofmann F, Stasch JP (2009) Handbook of experimental pharmacology. 191 cGMP generators, effectors and therapeutic implications. Preface. Handb Exp Pharmacol 191:v-vi
23. Ben Driss A, Devaux C, Henrion D, Duriez M, Thuillez C, Levy BI, Michel JB (2000) Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation 101(23):2764-2770 (Pubitemid 30390582)
24. Moraes DL, Colucci WS, Givertz MM (2000) Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102(14):1718-1723
25. Blair JE, Manuchehry A, Chana A, Rossi J, Schrier RW, Burnett JC, Gheorghiade M (2007) Prognostic markers in heart failure-congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care 9(4):207-213. doi: 10.1080/17482940701606913 (Pubitemid 350145787)
26. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MG, Selwyn AP, Alexander RW, et al. (1990) Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81(3):772-779 (Pubitemid 20090372)
27. Zeiher AM, Krause T, Schachinger V, Minners J, Moser E (1995) Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 91(9):2345-2352
28. Mitchell GF, Tardif JC, Arnold JM, Marchiori G, O'Brien TX, Dunlap ME, Pfeffer MA (2001) Pulsatile hemodynamics in congestive heart failure. Hypertension 38(6):1433-1439 (Pubitemid 34033429)
29. Ramsey MW, Goodfellow J, Jones CJ, Luddington LA, Lewis MJ, Henderson AH (1995) Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation 92(11):3212-3219
30. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ (2001) Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104(19):2305-2310 (Pubitemid 33049513)
31. Massion PB, Feron O, Dessy C, Balligand JL (2003) Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93(5):388-398. doi: 10.1161/01.RES.0000088351.58510.21 (Pubitemid 37100003)
32. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, Lindsey ML, Vancon AC, Huang PL, Lee RT, Zapol WM, Picard MH (2001) Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104(11):1286-1291 (Pubitemid 32848119)
33. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, Ferrari R (1999) Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 100(19):1983-1991 (Pubitemid 29529291)
34. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2(3):243-249
35. Maxwell AJ, Schauble E, Bernstein D, Cooke JP (1998) Limb blood flow during exercise is dependent on nitric oxide. Circulation 98(4):369-374 (Pubitemid 28348060)
36. Prasad A, Higano ST, Al Suwaidi J, Holmes DR Jr, Mathew V, Pumper G, Lennon RJ, Lerman A (2003) Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am Heart J 146(3):549-554. doi: 10.1016/S0002-8703(03)00364-8 (Pubitemid 37083093)
37. Bachetti T (2000) Endothelial dysfunction in chronic heart failure: some new basic mechanisms. Ital Heart J 1(10):656-661
38. Bank AJ, Lee PC, Kubo SH (2000) Endothelial dysfunction in patients with heart failure: relationship to disease severity. J Card Fail 6(1):29-36 (Pubitemid 30161414)
39. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A (2005) Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111(3):310-314. doi: 10.1161/01.CIR.0000153349.77489.CF (Pubitemid 40165337)
40. Mathier MA, Rose GA, Fifer MA, Miyamoto MI, Dinsmore RE, Castano HH, Dec GW, Palacios IF, Semigran MJ (1998) Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 32(1):216-224 (Pubitemid 28351065)
41. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, Drexler H (2005) Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 26(1):65-69. doi: 10.1093/eurheartj/ ehi001 (Pubitemid 40221125)
42. Poelzl G, Frick M, Huegel H, Lackner B, Alber HF, Mair J, Herold M, Schwarzacher S, Pachinger O, Weidinger F (2005) Chronic heart failure is associated with vascular remodeling of the brachial artery. Eur J Heart Fail 7(1):43-48. doi: 10.1016/j.ejheart.2004.04.008 (Pubitemid 40092490)
43. Meyer B, Mortl D, Strecker K, Hulsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R (2005) Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 46(6):1011-1018. doi: 10.1016/j.jacc.2005.04.060 (Pubitemid 41316508)
44. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND (2005) A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression. J Appl Physiol 98(1):203-210. doi: 10.1152/japplphysiol.00463.2004 (Pubitemid 40041248)
45. Murakami T, Mizuno S, Ohsato K, Moriuchi I, Arai Y, Nio Y, Kaku B, Takahashi Y, Ohnaka M (1999) Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 84(1):92-94, A98 (Pubitemid 29307648)
46. Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101(16):1899-1906 (Pubitemid 30225269)
47. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101(9):948-954 (Pubitemid 30131694)
48. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106(6):653-658 (Pubitemid 34851922)
49. Brevetti G, Silvestro A, Schiano V, Chiariello M (2003) Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 108(17):2093-2098 (Pubitemid 37337585)
50. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A (2003) The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 42(6):1037-1043 (Pubitemid 37108590)
51. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G (1998) Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98(24):2709-2715 (Pubitemid 28564006)
52. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, Lefer DJ (2003) Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 100(8):4891-4896. doi: 10.1073/pnas.0837428100 (Pubitemid 36457824)
53. Pacher P, Schulz R, Liaudet L, Szabo C (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26(6):302-310 (Pubitemid 40733523)
54. Schmidt HH, Hofmann F, Stasch JP (2009) Preface. In: Hofmann F (ed) cGMP: generators, effectors and therapeutic implications, vol 191. Handb Exp Pharmacol. Springer, Berlin, pp v-vi
55. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5(9):755-768 (Pubitemid 44323702)
56. Hobbs AJ, Stasch JP (2010) Soluble guanylate cyclase: allosteric activation and redox regulation. In: Ignarro LJ (ed) Nitric oxide: biology and pathobiology. (2nd edn). Academic Press, pp 301-326
57. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5(9):755-768. doi: 10.1038/nrd2038 (Pubitemid 44323702)
58. Gladwin MT (2006) Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest 116(9):2330-2332. doi: 10.1172/JCI29807 (Pubitemid 44330131)
59. Munzel T, Genth-Zotz S, Hink U (2007) Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? Hypertension 49(5):974-976. doi: 10.1161/HYPERTENSIONAHA.106.085456 (Pubitemid 351664319)
60. Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch JP, Bode C, Schmidt HH, Peter K (2011) Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis 218(2):431-434. doi: 10.1016/j.atherosclerosis.2011.06.042
61. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun kumar HS, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116(9):2552-2561. doi: 10.1172/JCI28371 (Pubitemid 44330154)
62. Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123(20):2263-2273. doi: 10.1161/CIRCULATIONAHA.110.981738
63. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R (2009) Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119(21):2781-2788. doi: 10.1161/CIRCULATIONAHA.108.800292
64. Gheorghiade M, Erdmann E, Ferrari R, Filippatos G, Levy P, Maggioni A, Mebazaa A, Nowack C (2011) Treatment of acute decompensated heart failure with the soluble guanylate cyclase activator cinaciguat: The COMPOSE program - three randomized, controlled, phase IIb studies. J Card Fail 17(11):971. doi: 10.1016/j.cardfail.2011.10.004
65. Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, Beuve A, van den Akker F (2010) Structure of cinaciguat (BAY 58-2667) bound to nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem 285(29):22651-22657
66. Stasch JP, Hobbs AJ (2009) NO-independent, haem-dependent soluble guanylate cyclasestimulators. Handb Exp Pharmacol (191):277-308
67. Thoonen R, Buys E, Cauwels A, Rogge E, Nimmegeers S, Van den Hemel M, Hochepied T, Van de Voorde J, Stasch JP, Brouckaert P (2009) NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go. BMC Pharmacol 9 (Suppl. 1):S41 (abstr)
68. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, Radtke M, Schirok H, Schlemmer KH, Stahl E, Straub A, Wunder F, Stasch JP (2009) Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4(5):853-865
69. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, Furstner C (2001) NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 11(6):781-784 (Pubitemid 32230679)
70. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A (2002) Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135(2):333-343 (Pubitemid 34151165)
71. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M (2002) Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135(2):344-355. doi: 10.1038/sj.bjp.0704483 (Pubitemid 34151166)
72. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410(6825):212-215 (Pubitemid 32216593)
73. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten H, Schindler PW, Busch AE, Sohn M, Topfer A, Pistorius A, Jannek C, Mulsch A (2006) Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 69(4):1260-1268
74. Masuyama H, Tsuruda T, Sekita Y, Hatakeyama K, Imamura T, Kato J, Asada Y, Stasch JP, Kitamura K (2009) Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 32(7):597-603
75. Jones ES, Kemp-Harper B, Stasch JP, Schmidt H, Widdop RE (2009) Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. BMC Pharmacol 9(Suppl 1):P29 (abstr)
76. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, Wellkisch K, Geschka S, Relle K, Hocher B, Stasch JP (2010) Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 28(8):1666-1675
77. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr (2003) Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107(5):686-689 (Pubitemid 36222594)
78. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, Kitamura K, Eto T (2006) Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 48(5):972-978 (Pubitemid 44611012)
79. Schafer A, Fraccarollo D, Werner L, Bauersachs J (2010) Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res Official J Italian Pharmacol Soc 62(5):432-438. doi: 10.1016/j.phrs.2010.06.008
80. Benz K, Orth SR, Simonaviciene A, Linz W, Schindler U, Rutten H, Amann K (2007) Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res 30(4):224-233 (Pubitemid 47076219)
81. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, Schmidt HH (2004) Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 101(47):16671-16676 (Pubitemid 39557771)
82. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ (2004) Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101(5):1386-1391 (Pubitemid 38182698)
83. Sovershaev MA, Egorina EM, Hansen JB, Østerud B, Stasch JP, Evgenov OV (2009) Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor. Arterioscl Thromb Vasc Biol 29(10):1578-1586
84. Peters H, Wang Y, Loof T, Martini S, Kron S, Kramer S, Neumayer HH (2004) Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Kidney Int 66(6):2224-2236. doi: 10.1111/j.1523-1755.2004.66012.x (Pubitemid 41115285)
85. Hohenstein B, Daniel C, Wagner A, Stasch JP, Hugo C (2005) Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 288(4):F685-693. doi: 10.1152/ajprenal.00280.2004 (Pubitemid 40381735)
86. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H (2005) Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 68(1):47-61. doi: 10.1111/j.1523-1755.2005.00380.x (Pubitemid 43181363)
87. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H (2006) Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 290(1):F167-F176. doi: 10.1152/ajprenal.00197.2005
88. Alter M, Ott I, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Kretschmer A, Stasch J-P, Hocher B (2011) Additional stimulation of sGC on top of standard treatment with ARB's may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone. BMC Pharmacol 11(Suppl 1):P1
89. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, Hocher B (2006) NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 148(6):853-859. doi: 10.1038/sj.bjp.0706792 (Pubitemid 44079415)
90. Hoffman L (2009) http://digital.bibliothek.uni-halle.de/hs/content/ titleinfo/711081. Accessed: November 10, 2011
91. Mitrovic V, Swidnicki B, Ghofrani A, Mück W, Kirschbaum N, Mittendorf J, Stasch JP, Wensing G, Frey R, Lentini S (2009) Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. BMC Pharmacology 9 (1):P51 (abstr)
92. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV (2008) Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 1(3):200-208 (Pubitemid 352831522)
93. Doi K, Noiri E, Sugaya T (2010) Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care. Curr Opin Crit Care. doi: 10.1097/MCC.0b013e32833e2fa4